UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

The Lancet (British edition), 2013-03, Vol.381 (9871), p.1021-1028

2013

Link zum Volltext

Verfügbarkeit prüfen

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

Vaccine, 2015-07, Vol.33 (30), p.3592-3599

2015

Link zum Volltext

Verfügbarkeit prüfen

The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults

American journal of respiratory and critical care medicine, 2010-06, Vol.181 (12), p.1407-1417

2010

Link zum Volltext

Verfügbarkeit prüfen

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study

The lancet respiratory medicine, 2017-04, Vol.5 (4), p.282-290

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Vaccine, 2017-03, Vol.35 (12), p.1652-1661

2017

Link zum Volltext

Verfügbarkeit prüfen

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial

Vaccine, 2021-09, Vol.39 (40), p.5822-5830

2021

Link zum Volltext

Verfügbarkeit prüfen

T-cell activation is an immune correlate of risk in BCG vaccinated infants

Nature communications, 2016-04, Vol.7 (1), p.11290-11290, Article 11290

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies

Vaccine, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

Vaccine, 2012-03, Vol.30 (12), p.2098-2108

2012

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis

Clinical pharmacology in drug development, 2021-07, Vol.10 (7), p.807-817

2021

Link zum Volltext

Verfügbarkeit prüfen

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3)

Vaccine, 2015-04, Vol.33 (15), p.1890-1896

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

American journal of respiratory and critical care medicine, 2017-05, Vol.195 (9), p.1171-1180

2017

Link zum Volltext

Verfügbarkeit prüfen

The US cap and trade initiative: current status and potential impact on business

American journal of business, 2013-04, Vol.28 (1), p.7-18

2013

Link zum Volltext

Verfügbarkeit prüfen

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

Vaccine, 2015-04, Vol.33 (15), p.1890-1896

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

The Lancet infectious diseases, 2021-04, Vol.21 (4), p.493-506

2021

Link zum Volltext

Verfügbarkeit prüfen

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON® -TB Gold (+) Kenyan adults without evidence of tuberculosis

Vaccine, 2016-05, Vol.34 (21), p.2430-2436

2016

Link zum Volltext

Verfügbarkeit prüfen

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG

Tuberculosis (Edinburgh, Scotland), 2013-03, Vol.93 (2), p.143-149

2013

Link zum Volltext

Verfügbarkeit prüfen

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses

Vaccine, 2014-10, Vol.32 (45), p.5908-5917

2014

Link zum Volltext

Verfügbarkeit prüfen

Covariant quantization of chiral bosons and OSp(1, 1|2) symmetry

Nuclear physics. B, 1990-10, Vol.343 (3), p.689-704

1990

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of the Ad35/AERAS-402 tuberculosis vaccine in a phase 2 dose-finding clinical trial in BCG-vaccinated healthy infants (VAC5P.1119)

The Journal of immunology (1950), 2015-05, Vol.194 (1_Supplement), p.73-73.4

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(95)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(118)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

The Novel Tuberculosis Vaccine, AERAS-402, Induces Robust and Polyfunctional CD4+ and CD8+ T Cells in Adults

Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial

T-cell activation is an immune correlate of risk in BCG vaccinated infants

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3)

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

The US cap and trade initiative: current status and potential impact on business

Correction: Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON® -TB Gold (+) Kenyan adults without evidence of tuberculosis

Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses

Covariant quantization of chiral bosons and OSp(1, 1|2) symmetry

Safety and immunogenicity of the Ad35/AERAS-402 tuberculosis vaccine in a phase 2 dose-finding clinical trial in BCG-vaccinated healthy infants (VAC5P.1119)

Suchergebnisse filtern